LYN SUE KAHNG
Osteopathic Medicine at Taylor St, Chicago, IL

License number
Illinois 036-107846
Category
Osteopathic Medicine
Type
Gastroenterology
Address
Address
1740 W Taylor St, Chicago, IL 60612
Phone
(866) 600-2273
(312) 996-6387
(312) 996-5103 (Fax)

Professional information

Lyn Sue Kahng Photo 1

Lyn Sue Kahng, Chicago IL

Specialties:
Internal Medicine, Gastroenterology
Work:
University of Illinois at Chicago
1801 W Taylor St, Chicago, IL 60612 Chicago Health Care System - West Side Div. - Jessie Brown Hospital
820 S Damen Ave, Chicago, IL 60612
Education:
University of California at San Francisco (1992)


Lyn Sue Kahng Photo 2

Dr. Lyn Sue Kahng, Chicago IL - MD (Doctor of Medicine)

Specialties:
Gastroenterology
Address:
UIC @ Chicago Digestive Disease
1801 W Taylor St STE C3, Chicago 60612
(312) 996-6651 (Phone)
Certifications:
Gastroenterology, 1998, Internal Medicine, 1995
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
UIC @ Chicago Digestive Disease
1801 W Taylor St STE C3, Chicago 60612
University of Illinois Hospital & Health Science System
1740 West Taylor St, Chicago 60612
Education:
Medical School
University Of California, San Francisco, School Of Medicine
Graduated: 1992
University Of California San Francisco
Graduated: 1993
Graduated: 1995
Stanford University


Lyn Kahng Photo 3

Treatment Of Bacterial Induced Diseases Using Dna Methyl Transferase Inhibitors

US Patent:
2005022, Oct 13, 2005
Filed:
Jul 9, 2003
Appl. No.:
10/615703
Inventors:
Stephen Benkovic - State College PA, US
Lucy Shapiro - Stanford CA, US
Rachel Wright - Menlo Park CA, US
Craig Stephens - Mountain View CA, US
Lyn Kahng - Chicago IL, US
Anthony Berdis - State College PA, US
Irene Lee - State College PA, US
International Classification:
A61K048/00
US Classification:
514044000
Abstract:
Methods for treating and/or preventing disease conditions caused or induced or aggravated by microbes, especially bacteria, by inhibiting DNA methyltransferase activity, such as by administering to an animal a DNA methyltransferase inhibitor, are disclosed, along with methods of reducing or ablating virulence in bacteria by inhibiting DNA methyltransferase activity.